What is Medeia?
Established in 1992, Medeia Inc has carved out a specialized niche in the manufacture and distribution of Neuro Diagnostic and Heart Rate Variability products. The company provides a comprehensive suite of biometrical software and hardware designed for precise physiological monitoring. Their flagship offerings, including the BrainView NeuralScan and the VitalScan cardiovascular series, serve a broad spectrum of medical professionals ranging from neurologists to primary care practitioners. By integrating advanced EEG technology with cognitive assessment tools, Medeia Inc facilitates critical research and educational advancements, maintaining a robust presence in the medical device market through consistent innovation and technical reliability.
How much funding has Medeia raised?
Medeia has raised a total of $1.6M across 2 funding rounds:
Other Financing Round
$1.5M
Debt
$150K
Other Financing Round (2007): $1.5M with participation from Brook Venture Partners
Debt (2020): $150K led by PPP
Key Investors in Medeia
Brook Venture Partners
A venture capital firm focused on expansion-stage businesses, providing both capital and hands-on corporate development support to technology-driven enterprises.
PPP
Public-Private Partnership
What's next for Medeia?
With the recent infusion of capital, Medeia Inc is poised to enter a new phase of enterprise-level scaling. The strategic focus will likely shift toward enhancing the interoperability of their existing diagnostic platforms and expanding their footprint in the digital health ecosystem. By prioritizing the integration of AI-driven analytics into their current hardware, the company aims to streamline clinical workflows and improve the diagnostic accuracy of their neuro-cognitive assessment tools. This growth phase is expected to solidify their competitive advantage, ensuring that their legacy in medical instrumentation continues to evolve alongside modern healthcare demands for real-time, actionable physiological data.
See full Medeia company page
